Life Science group Addlife has acquired the Austrian-based competitor Biomedica. Biomedica supplies products and services in the fields of laboratory technology and pharmaceutical technology in publicly funded healthcare. To fund the acquisition, Addlife has announced a rights issue worth SEK 500m. Biomedica reported a turnover of EUR 65m and EBITDA of EUR 4.4m by March 2018, corresponding to an EV/EBITDA multiple of 8.9x.
